[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer]

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer] Abstract Text:

Jun-ling Li,Xiang-ru Zhang,Ji-wei Liu,Zhong-yuan Chen,Ying-cheng Lin,Yuan-dong Wang,Qiang Chen,Ke-jun Nan,Shu-ping Song,Fu-cai Han,Yun-zhong Zhu,Long-yun Li,Yu-hong Zheng,Da-Tong Chu,Jun-ling Li,Xiang-ru Zhang,Ji-wei Liu,Zhong-yuan Chen,Ying-cheng Lin,Yuan-dong Wang,Qiang Chen,Ke-jun Nan,Shu-ping Song,Fu-cai Han,Yun-zhong Zhu,Long-yun Li,Yu-hong Zheng,Da-Tong Chu,

OBJECTIVE: The purpose of this phase I/II study is to investigate the safety/toxicity profile of weekly administration of docetaxel in combination with cisplatin for the chemo-naive patients with advanced non-small cell lung cancer (NSCLC), and to evaluate the efficacy of this regime. METHODS: In phase I trial, 15 patients were included. IV infusion of escalating doses of docetaxel consisting of four levels from 25 to 40 mg/m2 (25, 30, 35, 40 mg/m2) on D1, 8, 15 and cisplatin of 75 mg/m2 on D1 was administered. The regime was repeated every 4 weeks. Blood samples were obtained on D1, 15 in the first cycle to measure the PK. Dose limiting toxicity (DLT) was determined in cycle 1 and defined as any grade 3 non-hematologic toxicity which could not be reverted into grade less than grade 2 within 4 days or any grade 4 hematologic toxicity. Eighty-three patients completed their phase II study with administration of docetaxel at a dose of 35 mg/m2 based on the data of phase I trial. RESULTS: In the phase I trial, grade 3/4 neutropenia was mainly observed in patients who received docetaxel of 40 mg/m2 (level 4) with one patient suffering from an infection signifying dose limiting toxicity (DLT). Non-hematological toxicities including nausea/vomiting, alopecia, fluid retension and asthenia were tolerable. Based on these data, the maximum tolerence dose (MTD) did not reach the level of weekly giving docetaxel at a dose of 40 mg/m2 in combination with cisplatin 75 mg/m2 every 4 weeks. The pharmacokinetic/dynamics results There was no statistically significant difference between clearance value among the 4 dose levels of docetaxel from 25 to 40 mg/m2 when measured by Cmax and AUC. The pharmacokinetics of docetaxel was not influenced by the presence of co-administration of cisplatin when compared D1 with D15 as based on CmaxN, AUCN and CL. In the phase II trial, totally 83 patients received 216 cycles of chemotherapy. One CR (complete response) and 22 PR (partial response) were achieved with an objective response rate of 27.7% in this series and 30.7% in the evaluable patients. The 1-year survival was 48.6% with a median survival of 10.7 months (range: 3-34 months). Hematologic toxicities were the major side effects, though most were mild; grade III/IV neutropenia developed in 15%. The common non-hematologic toxicities were nausea, vomiting and asthenia. CONCLUSION: Weekly consecutive administration of docetaxel on D1, 8, 15 for 3 weeks plus cisplatin on D1 is tolerable and effective with minimal myelosuppression in chemo-naive patients with advanced NSCLC.

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer] Publishing Authors By Initials

JL Li,XR Zhang,JW Liu,ZY Chen,YC Lin,YD Wang,Q Chen,KJ Nan,SP Song,FC Han,YZ Zhu,LY Li,YH Zheng,DT Chu,JL Li,XR Zhang,JW Liu,ZY Chen,YC Lin,YD Wang,Q Chen,KJ Nan,SP Song,FC Han,YZ Zhu,LY Li,YH Zheng,DT Chu,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer] Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Zhonghua zhong liu za zhi [Chinese journal of onco

VOLUME: 28

Page Numbers: 309-12

Journal Abbreviation:

ISSN: 0253-3766

DAY: 31

MONTH: Apr

YEAR: 2006

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer] Information

Number of References:

LANGUAGE: chi

NlmUniqueID: 7910681

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer] Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer] Information

Substance Name:

Registry Number:

Grant and Affiliation Information for [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer]

AFFILIATION: Department of Medical Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences and Peaking Union Medical College; Beijing 100021, China.

Country: China

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Zhonghua Zhong Liu Za Zhi

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer Related Publications

• A deficient TLR2 signaling promotes airway mucin production in Mycoplasma pneumoniae-infected allergic mice.
• An image-based approach to measure the ferric ion diffusion coefficient in fricke gel dosimetry.
• Assays for nonhomologous end joining in extracts.
• Backpropagation Neural Network for Motion Analysis on Blood-pool Gated Single Photon Emission Computed Tomography.
• Determination of reaction intermediate structures in heme proteins.
• Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study.
• EUS could detect ascites missed by CT scan.
• Effects of growth factors on cell migration and alkaline phosphatase release.
• Enantioselective synthesis and antiviral activity of purine and pyrimidine cyclopentenyl C-nucleosides.
• Familial resemblance of adiposity-related parameters: results from a health check-up population in Taiwan.
• Heterogeneous reactions of SO2 with HOCl and HOBr on ice surfaces.
• IL-23-dependent IL-17 production is essential in neutrophil recruitment and activity in mouse lung defense against respiratory Mycoplasma pneumoniae infection.
• MUC1, MUC2 and MUC5AC expressions in cardiac myxoma.
• Measuring the folding transition time of single RNA molecules.
• Mutation accumulation in the intestine and colon of mice deficient in two intracellular glutathione peroxidases.
• PAMAM dendrimers and branched polyethyleneglycol (nanoparticles) prodrugs of (-)-beta-D-(2R, 4R)-dioxolane-thymine (DOT) and their anti-HIV activity.
• Scale-up development of high-performance polymer matrix for DNA sequencing analysis.
• Synthesis of neplanocin F analogues as potential antiviral agents.
• Water soluble complexes of chitosan-g-MPEG and hyaluronic acid.
• [Calpain I inhibition prevents pacing-induced structural remodeling for atrial fibrillation in canine]
• [Coronary artery atherosclerotic plaque and stent visualizations by optical coherence tomography]
• [Correlation between the serum levels of interleukin-2 and soluble interleukin-2 receptor and the response to immunosuppressive therapy in severe aplastic anemia patients]
• [Dynamic changes and significance of serum TNF-alpha, IL-8 levels in patients with acute respiratory distress syndrome after severe trauma]
• [Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer]
• [Lead expelling effect of carboxymethyl chitosan calcium in lead poisoned mice]
• [Natural killer-like T-cell lymphoma/leukemia--a case report and literature review]
• [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer]
• [Polymorphism of HLA-DRB1 in Han population in Yunnan and comparison with 9 Han populations]
• [Risk factors for postoperative gastroparesis syndrome after pancreaticoduodenectomy with binary logistic regression.]
• [Visualization of intimal proliferation of drug-eluting stent and bare mental stent by use of optical coherence tomography]